{"name":"Byondis B.V.","slug":"byondis-b-v","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"(vic-)trastuzumab duocarmazine","genericName":"(vic-)trastuzumab duocarmazine","slug":"vic-trastuzumab-duocarmazine","indication":"HER2-positive breast cancer","status":"phase_3"}]}],"pipeline":[{"name":"(vic-)trastuzumab duocarmazine","genericName":"(vic-)trastuzumab duocarmazine","slug":"vic-trastuzumab-duocarmazine","phase":"phase_3","mechanism":"Trastuzumab duocarmazine is an antibody-drug conjugate that binds HER2-positive cancer cells and delivers a DNA-damaging payload intracellularly.","indications":["HER2-positive breast cancer","HER2-positive gastric cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOWGxYdTkxZVlwQmo0OVJxaS0yUXBfV2kyVUVvTkJiY09YejdyVnQ3TFpVajktY2MtLURfdWpoZElfbkNsLW9zUDNrRE4tUzBZU1BkUlc3WUplZTZqby13WE0yVWlPdnJ2NWp0RHkzVzlMczYxVnpUaVR6UVNnZ21TTjEzcENqS1N2dUhEM0FZajEzaGF1d01uWl9sakRSMXdaZjdxRTJkT1JHNUk?oc=5","date":"2025-03-25","type":"pipeline","source":"BioSpace","summary":"Byondis Appoints Christoph Korpus, PhD, MBA, as Chief Business Officer - BioSpace","headline":"Byondis Appoints Christoph Korpus, PhD, MBA, as Chief Business Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxObkthRG1JUUV1Z081cHY0bk9OcVBpVUFRd1BBMGUtajVZazJpelBLVVF6bGR4R09TYU5RYmluQnE5V29BdDhDWk1rOUQ0NVJuSGRBQWM1YzRrN0RraThvdm1PRlJlUnlMRDgtUWRDbFpmYjhWVWhLcXdkdS1QOHh0LVo4VjdDc1lTZS1ubmdYaHlsQlF3Ump4NFpTNHhYUTlrLXhCem54bDR6em93WmFPQVdtZnBlQQ?oc=5","date":"2024-11-19","type":"pipeline","source":"Business Wire","summary":"Byondis Appoints Louis Denis, M.D., as Chief Medical Officer - Business Wire","headline":"Byondis Appoints Louis Denis, M.D., as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNbDVNY2Vtekhac0k0RU5Rc0hGN3FTVFA2UTRaMlRvbnduYW54TEtEUFpmdjIzYWUxQ1k1Rmt4R3JtVEtPTkFQMWRhTmxtOEctdGJMN0RCSlJ2dWxsWWRkN0xucC1ETkxZSnhEX0JEeGZVTXpTMjZSeDJwbWphbGRQa3lNTEFkTG5XOUZDZ1ZSa0JXWFlUbGFhRDZ0M29QSlIxQUg1Rk8wMXlUUEFEWG5CQndyS0tDQVp2T2tmM0lzeTZRSEtIbk1DVzY3ZWVpX0RZcWJ6MWtSS0FJd21JTTNwVXcxeHpBSXJlVHl3MmIxMUtlQWVLaVlfTVhvWUdobkRiVDFTM0pkWTFYSHo4RjN3TU1VYUV5dk1XZjRya3ptcUwwREpUamVveE9QYU4zSUxSU3djOWZNTQ?oc=5","date":"2024-10-01","type":"trial","source":"GlobeNewswire","summary":"Breast Cancer Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"Breast Cancer Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxOTHRVcHBCWXJDTkhFWXFjV1hNMXo3dXZMTFk1SGktQzRLeWw1OEpzNjdMWTlKVmpna1YxeGxfaURlX3VBNkJzc01mLWhFTDlMQk9GMUtiVEdhQUQ3bkktSWQtTWhjanZ0MlVQeU9WX29wSjMtUTVLRmoyRjkyMmZseFFzS2dpT19adE1PX0FhazkzZ3VtYnlJNy1JSmhVcEhKQnR1bGlQSFJ4YkRobTVUeWJSVnFIU19FekhTVnRad2pOeGdJTml1VG8zOGFMYWpOdkJaNVVMMG9TRnd2eDA0ZlNjSUpsZlZUcmpmVF9NcUtHX0pDdkpST1lDaTEzSzB4Z3phczRpYzdHaTQ4ci00?oc=5","date":"2022-05-03","type":"deal","source":"PR Newswire","summary":"Byondis and medac Enter Into License and Collaboration and Supply Agreements for Anti-HER2 ADC Trastuzumab Duocarmazine (SYD985) - PR Newswire","headline":"Byondis and medac Enter Into License and Collaboration and Supply Agreements for Anti-HER2 ADC Trastuzumab Duocarmazine ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOaG9fVUJXWW03S2hxZXY4OVBrRUhTMC1kZFV6VnF3UEdEU091U2RQVk9obUlMUGdvWHdmZ0picXZKVjFFUjlmdVZYTTdUTUVLTWhHVkliR0Q2YTV2eVJHZUR0WWxub2cwcVBQSlBMRE8xUmNNc0FZcTZTeURldWdVREdzMWZxMHI3X0lxWFcyb0IzY3VnVk5IdjAwWTk4eUNWODFnY1NNRW1YRVBDb0pBcWIzYUI?oc=5","date":"2022-05-03","type":"deal","source":"Contract Pharma","summary":"Byondis Partners with Medac to Commercialize Antibody-Drug Conjugate - Contract Pharma","headline":"Byondis Partners with Medac to Commercialize Antibody-Drug Conjugate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQdXd1QmRORHBOV2pyMUZjOGctYzVMMTJVVFNucEJiWU1zQjRsSngyUkRVTEZaRUl3a0ZiUDE2TVo1X3o4ODFQa0tZMVNEZzhLS3c4Q01mOVdCNThfWllLMFNjRDF6dTVWLUpLWURMUmI3c3ZBZDZWQ0dYdEpnN2JvYnM5a18?oc=5","date":"2021-08-14","type":"pipeline","source":"PharmaLive","summary":"New senior director, immuno-oncology R&D, for Byondis - PharmaLive","headline":"New senior director, immuno-oncology R&D, for Byondis","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}